[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 1977

Primary Acquired Cold UrticariaDouble-Blind Comparative Study of Treatment With Cyproheptadine, Chlorpheniramine, and Placebo

Author Affiliations

From the Department of Pediatrics, University of Colorado Medical Center and the National Jewish Hospital of Denver (Dr Wanderer) and the Department of Pediatrics, State University of New York at Buffalo (Dr Ellis). Dr Jean-Paul St. Pierre is in private practice in Montreal.

Arch Dermatol. 1977;113(10):1375-1377. doi:10.1001/archderm.1977.01640100053005
Abstract

• Eight subjects with primary-acquired cold urticaria were treated with chlorpheniramine maleate, cyproheptadine hydrochloride, and placebo in a double-blind clinical trial. During three separate seven-day treatment periods, each patient took 4 mg of either active drug or lactose placebo three times a day. Objective measurements were made at the beginning and end of each treatment period by establishing the minimum time (MT) of cold stimulus application required to provoke urtication. In addition, the spontaneous appearance of cold urticaria lesions was recorded during each treatment period. The MT required for induction of urtication with a cold stimulus was significantly greater for eight patients receiving cyproheptadine as compared to chlorpheniramine or placebo (P < .01). The study demonstrated that cyproheptadine had a significant suppressive action on experimental cold-induced urticaria, while placebo and chlorpheniramine proved ineffective.

(Arch Dermatol 113:1375-1377, 1977)

×